Skip to content

A Multicenter Prospective Observational Study of Tocilizumab in the Treatment of Rheumatoid Arthritis

A Multicenter Prospective Observational Study of Tocilizumab in the Treatment of Rheumatoid Arthritis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500113963
Enrollment
Unknown
Registered
2025-12-04
Start date
2025-12-08
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Observation group:No data

Sponsors

Affiliated Hospital of Gansu University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: All inclusion criteria were met for inclusion: (1) The patient's age >= was 18 years old; (2) Physician confirmed rheumatoid arthritis, compliant with 2010 ACR/EULAR established diagnostic criteria for ra classification; (3) Ra disease activity (DAS 28 >= 2.6); Good compliance, cooperate with follow-up.

Exclusion criteria

Exclusion criteria: Subjects who meet one of the following conditions will not be enrolled in the trial: (1) Live vaccination within 4 weeks before screening; (2) Patients with malignant tumor or history of malignant tumor and the risk of treatment is greater than the benefit judged by the investigator; (3) In the active stage of systemic or local infection, the risk of treatment is greater than the benefit judged by the investigator; (4) Severe hepatic and renal insufficiency; (5) Severe center of gravity and cerebrovascular disease; (6) Pregnant women and breast-feeding women; (7) Any biological agent within 4 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to initiation of tocilizumab treatment; (8) A person with mental illness, a history of alcoholism, immunodeficiency, drug or other substance abuse; (9) Those who are allergic to the ingredients of this product; Other circumstances judged by the investigator to be unsuitable for inclusion in the study.

Design outcomes

Primary

MeasureTime frame
Clinical efficacy;

Secondary

MeasureTime frame
Assess disease activity;Evaluating clinical efficacy based on higher standards;Assessing disease activity based on patient-reported outcomes;Assess quality of life;Evaluate drug safety;Assess the impact of drug use on hormone dosage;

Countries

China

Contacts

Public ContactXiexingwen

Affiliated Hospital of Gansu University of Traditional Chinese Medicine

782324684@qq.com+86 189 1900 9860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026